Search results
Showing 316 to 330 of 491 results for %s
Gambling-related harms: identification, assessment and management (NG248)
This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.
Read NICE's patient and public involvement policy.
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (HTG334)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
details of the evidence and the committee's discussion are in evidence review S: previous caesarean section . Source guidance details...
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making